7TH ESMO TOGETHER

NOVEMBER 7TH, 2026

AMPHI C

FACULTY OF MEDICINE - SAINT JOSEPH UNIVERSITY

BEIRUT , LEBANON

CME ACCREDITED

PROGRAM

Organized by
Department of Hematology Oncology
Faculty of Medicine – Saint Joseph of Beirut USJ

In Collaboration with
The Lebanese Society of Medical Oncology LSMO
Cancer Research Group, the Arab Medical Association
Against Cancer AMAAC and Gustave Roussy Alumni


WELCOME NOTE

We are pleased to announce the **7th ESMO Together 2026 Conference**, to be held on **November 7, 2026.**

We believe that this initiative, led by the Hematology-Oncology Department at the Faculty of Medicine - Saint Joseph University of Beirut, in collaboration with LSMO, AMAAC, the Cancer Research Group, and AMCI, will once again significantly contribute to our continuous medical education goals. This year's conference will be conducted virtually, within 2 weeks following the conclusion of the ESMO Congress in Berlin.

We would like to sincerely thank the CME Office at the Faculty of Medicine – Saint Joseph University of Beirut for accrediting this program.

"Together," we continue our mission of advancing medical education to provide the best care for our patients.



Prof. Marwan Ghosn, MD, MHHM
ESMO Together Chairman

THE 7TH ESMO TOGETHER 2026

NOVEMBER 7, 2026 | BEIRUT - LEBANON

09:30 - 10:10	**Welcoming and Introduction**	
09:30 - 09:35	Welcome Note | ESMO Together Chairman	Prof. Marwan Ghosn
09:35 - 09:40	Welcome Note | President of the AMAAC	Prof. Sami El Khatib
09:40 - 09:45	Welcome Note | President of the Cancer Research Group	Prof. Fadi Farhat
09:45 - 09:50	Welcome Note | President of AMCI	Prof. Hamdy Abdel Azim
09:50 - 09:55	Welcome Note | President of Gustave Roussy Alumni, Pre-Recorded	Prof. Karim Fizazi
09:55 - 10:00	Welcome Note | Chairman of the Department of Hematology Oncology - USJ	Prof. Joseph Kattan
10:00 - 10:05	Welcome Note | Vice-Recteur à la Recherche à l'USJ	Prof. Nassim Fares
10:05 - 10:10	Welcome Note | Dean Faculty of Medecine USJ	Prof. Elie Nemr

THE 7TH ESMO TOGETHER 2026

NOVEMBER 7, 2026 | BEIRUT - LEBANON

	Gustave Roussy Alumni Board, Special Participation	Dr. Elie El-Rassi
BREAST SESSION 1 Moderators: Prof. Nabil Chamseddine - Prof. Fadi Farhat		
10:10 - 10:20	ESMO in 10 points	Prof. Nabil Chamseddine
10:20 - 10:50	Keynote Lecture Treatment of early stage TNBC in 2026	Prof. Hamdy Abdel Azim
10:50 - 11:20	Symposium Sponsored by Roche Navigating HR+/HER2-mBC Cancer: Unmet Needs & Current Treatment Pardigm	Prof. Joseph Kattan
11:20 - 11:25	Breast Cancer HER2 Positive	Prof. Fadi Farhat
11:25 - 11:30	OptiTROP-Breast01 Final overall survival analysis of sacituzumab tirumotecan versus chemotherapy Abstract 4639RO · Rapid Oral	Prof. Adel Tabchy
11:30 - 11:35	Natalee: 6-Year Overall Survival And Efficacy For Adjuvant Ribociclib + Nonsteroidal Aromatase Inhibitor In Hr+/Her2− Early Breast Cancer.	Dr. Jad Wakim
11:35 - 11:40	Post- MONARCH and KeyNote B49: Positive on Paper, not in Practice	Dr. Elias Karam

THE 7TH ESMO TOGETHER 2026

NOVEMBER 7, 2026 | BEIRUT - LEBANON

11:40 - 11:55	Coffee Break	
BREAST CANCER SESSION 2 Moderator: Dr. Joseph Makdessi		
11:55 - 12:00	Randomized Phase 3 Study of Izalontamab Brengitecan (iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-negative (HR+/HER2-) Breast Cancer.	Dr. Abir El Ahmadie
12:00 - 12:05	ADC after ADC sequencing, switching payloads matter	Dr. Philippe Aftimos
12:05 - 12:35	Satellite Symposium Supported by Astrazeneca Transform HER destiny	Prof. Fadi El Karak
12:35 - 12:50	What Have We Learned In Breast Cancer from ESMO 2026?	Prof. Nagi El Saghir
12:50 - 13:20	Symposium Sponsored by Novartis From Risk of Recurrence to Overall Survival: Redefining Outcomes in HR+/HER2 Early Breast Cancer	Prof. Fadi El Karak

THE 7TH ESMO TOGETHER 2026

NOVEMBER 7, 2026 | BEIRUT - LEBANON

13:20 - 13:35	What Have We Learned from ESMO 2026? Except in Breast Cancer	Prof. Georges Chahine
HEMATOLOGY SESSION Moderator: Prof Marwan Ghosn		
13:35 - 13:40	Belantamab Mafodotin in Multiple Myeloma	Dr. Kayane Mheidly
13:40 - 13:50	ENABLE : A Phase 1 Study of ELVN-001, a Novel, Selective ATP-Competitive Inhibitor of BCR::ABL1, in Patients with Previously Treated CP-CML	Prof. Fadi Haddad
13:50 - 13:55	Special Side Effects of Bispecific Treatments in Hematology Presented at ESMO 2026	Mrs. Rebecca Khoueiry
13:55 - 14:00	Updates in Lymphomas	Dr. Colette Hanna
14:00 - 14:30	Symposium Sponsored by BMS Advances of Immunotherapy in Adjuvant and Metastatic Urothelial Carcinoma	Dr. Sally Tamraz
14:30 - 14:40	Certificates of Appreciation Ceremony	

THE 7TH ESMO TOGETHER 2026

NOVEMBER 7, 2026 | BEIRUT - LEBANON

14:40 - 15:10	Lunch Break	
14:40 - 15:10	Lunch Break Meeting | Gustave Roussy Alumni	
15:10 - 15:40	Symposium Sponsored by MSD Navigating New Frontiers in the Treatment Paradigm of Bladder Cancer	Dr. Hampig Kourie
URO ONCOLOGY Moderator: Dr. Ali Youssef		
15:40 - 15:45	Volga Perioperative Durvalumab + Enfortumab Vedotin in Cisplatin-Ineligible/Refusing Mibc	Prof. Joseph Kattan
15:45 - 15:50	Selected URO Oncology Prostate Abstracts	Prof. Deborah Mukherji
15:50 - 15:55	LBA4 - Darolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 trial (DASL-HiCaP; ANZUP1801)	Dr. Fares Azoury
15:55 - 16:00	Long-term overall survival with abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial for de novo metastatic castration-sensitive prostate cancer (mCSPC)	Dr. Rachel El Ferekh

THE 7TH ESMO TOGETHER 2026

NOVEMBER 7, 2026 | BEIRUT - LEBANON

16:00 - 16:30	Symposium Sponsored by PFIZER in Partnership with Droguerie Fattal Lorlatinib in the First-Line Treatment of ALK+ aNSCLC: 7-year Efficacy Outcomes and Safety Profile	Prof. Marwan Ghosn
LUNG Moderators: Dr. Marcel Massoud - Prof. Fadi El Karak		
16:30 - 16:35	Tarlatamab plus Durvalumab (Durva) vs Durva as First-Line (1L) Maintenance (1LM) Therapy Following Durva, Platinum and Etoposide (1L durva + EP) in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Primary Analysis of the Phase 3 DeLLphi-305 Trial	Dr. Anthony Saroufim
16:35 - 16:40	EGFR-Targeted Therapies: Practical Tips for Managing and Preventing Treatment-Related Toxicities	Dr. Janah Maddah
16:40 - 16:45	SARON – Consolidative Radiotherapy/SABR in Oligometastatic, Driver-Negative NSCLC (Randomised Phase II). Improved Local Control and PFS Without an OS Benefit; I Would Discuss Patient Selection, Possibly Alongside PE-PE (Pembrolizumab + Metastasis-Directed Therapy in Oligometastatic RCC).	Dr. Caroline Jabbour
16:45 - 17:00	Coffee Break	

THE 7TH ESMO TOGETHER 2026

NOVEMBER 7, 2026 | BEIRUT - LEBANON

17:00 - 17:30	Symposium Sponsored by J&J Rybrevant and Lazcluze Combined Power to Change the Game	Dr. Malek Safa
GASTROINTESTINAL AND OTHERS Moderators: Dr. Fouad Kerbage - Prof. Marwan Ghosn		
17:30 - 17:40	Selected Colorectal Cancer Abstracts	Dr. Hampig Kourie
17:40 - 17:45	MASTERPLAN — 3136RO Chemotherapy ± SBRT for High-Risk Pancreatic Cancer	Dr. Clement Khoury
17:45 - 17:50	Ivonescimab plus Chemotherapy versus durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: a randomized, controlled, double-blinded, phase 3 trial (HARMONi-GI1)	Dr. Alain Daher
17:50 - 17:55	Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Additional subgroup analyses from the ph3 RASolute 302 study	Dr. Roland Eid
17:55 - 18:00	HERIZON-GEA-01 (LBA79): Zanidatamab ± Tislelizumab Combined with Chemotherapy	Dr. Makram Khoury
18:00 - 18:05	Personalized mRNA Vaccines in Melanoma: Lessons from INTerpath-001	Dr. Mohamad Minhem

THE 7TH ESMO TOGETHER 2026

NOVEMBER 7, 2026 | BEIRUT - LEBANON

18:05 - 18:10	Abstract 2076RO (Sonja Witteveen) : NADINA: Three-Year Distant Metastasis-Free Survival With Neoadjuvant Immunotherapy in Stage III Melanoma	Dr. Celine Boutros
18:10 - 18:15	KEYNOTE-C93/GOG-3064/ENGOT-en15: Phase 3, Randomized, Open-Label Study of First-line (1L) Pembrolizumab (Pembro) vs Carboplatin (C) + Paclitaxel (P) in Mismatch Repair-Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (a/rEC)	Dr. Charbel Soueidy
18:15	Closing	Prof. Marwan Ghosn

GOLD SPONSOR

Johnson&Johnson Innovative Medicine

TAMINA HEALTHCARE

Pfizer

NOVARTIS KHALIL FATTAL ET FILS

SILVER SPONSOR

Roche

AstraZeneca What science can do

MSD

EXHIBITOR SPONSOR

mersaco BEYOND CARE

SANDOZ

CryoGene Targeting Advanced Technologies

Benta

ORGANIZED BY:

INFOMED

Innovating | Executing | Networking

UAE | Lebanon | Kuwait | Iraq